Table 1 of
Hayashida, Mol Vis 2020; 26:505-509. Table 1 of
Hayashida, Mol Vis 2020; 26:505-509.
Table 1. Patient demographic and baseline clinical characteristics.
| Factor | Good treatment response (n=53) | Poor treatment response (n=34) | P value |
|---|---|---|---|
| Age (years) | 55.1±12.3 | 61.1±16.2 | 0.11 |
| Sex (male/female) | 39/14 | 23/11 | 0.50 |
| Baseline BCVA (logMAR) | 0.13±0.27 | 0.21±0.28 | 0.069 |
| Smoking (+/−) | 14/39 | 9/25 | 0.59 |
| Disease duration (months) | 12.6±20.1 | 14.8±17.5 | 0.106 |
| Spot size (μm) | 4123.1±1175.5 | 4233.3±1361.6 | 0.71 |
| RPE alteration (+/−) | 33/20 | 20/14 | 0.46 |
| Hyperfluorescence on ICGA findings | 15/29/9 | 6/12/16 | 0.011 |
| (Intense/Intermediate/No) | |||
| Baseline CFT (μm) | 330.7±103.8 | 339.9±117.5 | 0.62 |
| Baseline SCT (μm) | 401.9±119.6 | 342.3±117.3 | 0.70 |